AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

Juan Carlos Serna, Senior Vice President of Scientific and Clinical Affairs at AngioDynamics

“Humana’s decision is an important step toward more consistent access to NanoKnife IRE for eligible patients”

Juan Carlos Serna, Senior Vice President of Scientific and Clinical Affairs at AngioDynamics

“Together with Category I CPT codes and Palmetto GBA’s final LCD, this policy represents another meaningful reimbursement milestone for the NanoKnife System and for the patients and physicians we serve.”

Xiaosong Meng, MD, PhD, Department of Urology at UT Southwestern Medical Center

“For men with favorable intermediate-risk prostate cancer, the choice often comes down to observing their cancer with active surveillance or undergoing radical treatments with potential side effects of therapy”

Xiaosong Meng, MD, PhD, Department of Urology at UT Southwestern Medical Center

“Focal therapies such as IRE give us another option for men with intermediate-risk prostate cancer while working to protect the structures that matter to a patient's quality of life.”

Xiaosong Meng, MD, PhD, Department of Urology at UT Southwestern Medical Center

“Access depends on coverage, and policies like this one help ensure that the treatment decision rests with the patient and physician, not with where the patient lives or which plan they have.”